Dynorphin A, dynorphin B, and alpha-neoendorphin differentially regulated the human kappa opioid receptor — different internalization, signaling, and desensitization patterns despite all being kappa agonists — biased agonism from natural ligands.
Key findingDifferent prodynorphin-derived peptides (dynorphin A, dynorphin B, alpha-neoendorphin) showed differential kappa receptor regulation: distinct pattern
What the researchers found
Different prodynorphin-derived peptides (dynorphin A, dynorphin B, alpha-neoendorphin) showed differential kappa receptor regulation: distinct patterns of internalization, signaling efficacy, and receptor recycling — demonstrating biased agonism from endogenous ligands.
Why it matters
Relevant for opioid-peptides, receptor-signaling.
How the study worked
in-vitro study on opioid-peptides, receptor-signaling.
What this study cannot tell us
See abstract.
How to read the evidence
preliminary evidence.
When this study was published
Published in 2007.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
- Clinical translation to evaluate.
Common questions
What was studied?
What was found?
Read the original research
Dynorphin peptides differentially regulate the human kappa opioid receptor.
Life sciences, 80(15), 1439-48
Citation
Chen, Yong; Chen, Chongguang; Liu-Chen, Lee-Yuan. (2007). Dynorphin peptides differentially regulate the human kappa opioid receptor.. Life sciences, 80(15), 1439-48.